Brief: UCB And Biogen Announce Positive DZP Phase 3 Study Results
BRIEF-UCB And Biogen Announce Positive DZP Phase 3 Study Results June 1 (Reuters) - Ucb SA UCB.BR:
UCB AND BIOGEN ANNOUNCE PUBLICATION IN LANCET OF POSITIVE DAPIROLIZUMAB PEGOL (DZP) PHASE 3 STUDY RESULTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
RESULTS SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN DISEASE ACTIVITY WITH DZP VERSUS PLACEBO
Source text: https://tinyurl.com/be5uxddb
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova